Evidence map›Paper›PMID 37393743›Full record

ArticleGynecologic oncology2023

Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.

Andre Konski, Snehal Deshmukh, Ann H Klopp, Anamaria R Yeung, Shannon N Westin, J Spencer Thompson, Desiree E Doncals, Guilherme H C Cantuaria, David P D'Souza, Amy Chang and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 17 institutions in 4 countries.

Andre KonskiDepartment of Radiation Oncology, University of Pennsylvania, Senior Fellow Leonard Davis Institute of Health Economics, University of Pennsylvania, The Chester County Hospital, 701 E. Marshall Ave, West Chester, PA 19380, USA; Senior Fellow, Leonard Davis Institute for Health Economics, University of Pennsylvania, Department of Radiation Oncology, University of Pennsylvania, The Chester County Hospital, 701 E. Marshall Ave, West Chester, PA 19380, USA. Electronic address: andre.konski@uphs.upenn.edu.
Snehal DeshmukhAmerican College of Radiology, NRG Statistical and Data Management Center, NRG Oncology, 50 South 16th Street, Suite 2800, Philadelphia, PA 19102, USA.
Ann H KloppDepartment of Radiation Oncology, MD Anderson Cancer Center, Division of Radiation Oncology, 1515 Holcombe Boulevard, The University of Texas, Unit 1422, Houston, TX 77030, USA.
Anamaria R YeungDepartment of Radiation Oncology, University of Florida, 2000 Southwest Archer Road PO Box 100385 Gainesville, FL 32610, USA.
Shannon N WestinDepartment of Radiation Oncology, MD Anderson Cancer Center, Division of Radiation Oncology, 1515 Holcombe Boulevard, The University of Texas, Unit 1422, Houston, TX 77030, USA.
J Spencer ThompsonDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 Northeast Tenth Street, Fifth Floor, Oklahoma City, OK 73104, USA.
Desiree E DoncalsSUMMA Akron City Hospital/ Cooper Cancer Center, 161 North Forge Street, Suite G90, Akron, OH 44304, USA.
Guilherme H C CantuariaNorthside Hospital, University Gynecologic Oncology 960 Johnson Ferry Road Northeast Suite 130 Atlanta, GA 30342, USA.
David P D'SouzaLondon Regional Cancer Program, London Health Sciences Centre, 339 Windermere Road, P.O. Box 5339, Stn Z, London, Ontario N6A 5A5, Canada.
Amy ChangPamela Youde Nethersole Eastern Hospital, Main Block, Lok Man Rd, Chai Wan, Hong Kong.
Vijayananda KundapurSaskatoon Cancer Center, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Dasarahally S MohanKaiser Permanente Cancer Treatment Center, Department of Radiation Oncology, 220 Oyster Point Boulevard South, San Francisco, CA 94080, USA.
Michael L HaasDepartment of Radiation Oncology, McGlinn Cancer Institute Reading, Reading Hospital Radiation Oncology Department, 420 South Fifth Avenue West Reading, PA 19611, USA.
Yong Bae KimYonsei University Health System, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea.
Catherine L FergusonGeorgia Regents University, Augusta University Medical Center, Section of Hematology and Oncology, 1120 15th Street, BAA-5407 Augusta, GA 30912, USA.
Stephanie L PughAmerican College of Radiology, NRG Statistical and Data Management Center, NRG Oncology, 50 South 16th Street, Suite 2800, Philadelphia, PA 19102, USA.
Lisa A KachnicDepartment of Radiation Oncology, Columbia University, Herbert Irving Comprehensive Cancer Center, NYP/Columbia University Medical Center, Department of Radiation Oncology, 622 West 168th Street, New York, NY 10032, USA.
Deborah W BrunerEmory University Hospital/Winship Cancer Institute, 1599, Clifton Road, Northeast, Fourth Floor, Atlanta, GA 30322, USA.
The University of Texas MD Anderson Cancer Center · USAmerican College of Radiology · USAugusta University Health · USColumbia University Irving Medical Center · USEmory University Hospital · USKaiser Permanente · USLondon Health Sciences Centre · CANorthside Hospital · USNRG Oncology · USPamela Youde Nethersole Eastern Hospital · CNReading Hospital · USSumma Akron City Hospital · USUniversity of Florida · USUniversity of Oklahoma Health Sciences Center · USUniversity of Pennsylvania · USUniversity of Saskatchewan · CAYonsei University Health System · KR

Funding

NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muhammad Furqan · 2019 to 2026
$13.7M
NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233193
6 · The paper itself

Abstract

introductionNRG/RTOG 1203 compared 3-D conformal radiotherapy (3D CRT) to intensity-modulated radiotherapy (IMRT) in patients with endometrial or cervical cancer requiring post-operative radiotherapy after hysterectomy. The purpose of this study was to report the first quality-adjusted survival analysis comparing the two treatments.

methodsNRG/RTOG 1203 randomized patients having undergone hysterectomy to either 3DCRT or IMRT. Stratification factors included RT dose, chemotherapy, and disease site. The EQ-5D, both index and visual analog scale (VAS), were obtained at baseline, 5 weeks after the start of RT, 4-6 weeks post RT and 1 and 3-years post RT. EQ-5D index and VAS scores along with quality-adjusted survival (QAS) were compared between treatment arms using the t-test at a two-sided significance level of 0.05.

resultsNRG/RTOG 1203 enrolled 289 patients of which 236 consented to participate in the patient reported outcome (PRO) assessments. QAS was higher in women treated with IMRT, 1374 vs 1333 days (p = 0.5) compared to patients treated with 3DCRT, but this difference was not statistically different. Patients treated with IMRT had less of a decline in VAS score 5 weeks post RT, -5.04, compared to patients treated with 3DCRT, -7.48, although not statistically significant (p = 0.38).

conclusionThis is the first report of the use of the EQ-5D comparing two radiotherapy techniques in the treatment of gynecologic malignancies after surgery. While there were no significant differences in QAS and VAS scores between patients who received IMRT vs. 3DCRT, RTOG 1203 was not powered to show statistical differences in these secondary endpoints.

Indexed as

Genital Neoplasms, FemaleRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedUterine Cervical NeoplasmsFemaleHumansRadiotherapy DosageRadiotherapy Planning, Computer-AssistedCervical cancerEndometrial cancerIntensity modulated radiotherapy (IMRT)Patient reported outcomesUtilities

Identifiers

PMID37393743
PMCPMC10527270
OpenAlexW4382753522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.